V-POINT (Vanderbilt Program for
Optimizing ImmuNo-oncology Therapies)
The V-POINT Approach
Toxicities from immune checkpoint inhibitors remain poorly understood. Understanding why they occur in certain patients, how to best treat them, and optimizing care in health care systems are key unanswered questions. We have brought together physicians and scientists from a broad range of specialties to address these questions using clinical, translational, and basic science research.
Unleashing the immune system to fight cancer has been a major goal of medicine for over a century. Recently, a number of immune-based strategies have resulted in significant success. Particularly effective have been immune checkpoint inhibitors, at least for some cancer types. These treatments are now being used in many cancers globally.
V-POINT (Vanderbilt Program for Optimizing ImmuNo-oncology Therapies) is a multi-disciplinary effort at Vanderbilt to more effectively and safely use immune therapy in cancer patients, using cutting-edge basic science, clinical research, and education.
For Providers
Providers can visit this page to see a toxicity overview, resources and guidelines, as well as selected publications.
For Patients
Patients can visit this page to get an overview of immune therapy, toxicity, and links to additional resources.
Dr. Douglas Johnson, at left, leads the multidisciplinary V-POINT team.
Connect with V-POINT
Collaborations
V-POINT's success hinges on close collaboration among physicians and scientists, as well as experts across multiple subspecialties. Toxicities from immunotherapies affect every organ system, and we look forward to bringing together experts from every disease group for comprehensive patient care.
Research Opportunities
The V-POINT program is interested in recruiting talented physician-scientists and scientists from different organ disciplines.
If interested, please send inquiries to Kathryn Mashburn at k.mashburn@vumc.org.